Associated Papers
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Mukonzo JK et al.
Plos One, 2014
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
Mukonzo JK et al.
Clinical Pharmacokinetics, 2011
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.
Mukonzo JK et al.
British Journal of Clinical Pharmacology, 2009
Select a paper to view details